spacer
home > ict > Winter 2011
PUBLICATIONS

International Clinical Trials

ict
Winter 2011
   
Text
PDF
bullet
Regulatory & Business Practice
Mian Atif Saeed at Bristol-Myers Squibb argues that, although complex and lengthy, the drug development process has plenty of scope for changes to its usual framework that could help it become more streamlined, leaner and efficient.
 
view
download pdf
The huge cost to a project should it fail to meet compliance requirements compels imaging core labs to pay heed to 21 CFR Part 11. However, as Christian Teague at RadCore Labs, LLC and FDA Compliance Specialist David Nettleton point out, this can be seen as a positive step.
 
view
download pdf
Based on the principles of value management, Paul Naybour and Roger Joby at Parallel Project Training propose a collaborative approach to drug development feasibility studies, bringing the whole project team together to understand challenges and identify significant cost reduction strategies.
 
view
download pdf
bullet
TRIAL MANAGEMENT
Although randomised controlled trials provide more benefits than observational studies, the latter is becoming more common and therefore their statistical challenges need to be addressed. David J Pasta and Dave P Miller at ICON Clinical Research discuss two techniques that can be used to address group differences in these studies.  
view
download pdf
The cost of conducting early phase oncology studies has increased substantially over the last decade. However, the future holds the prospect of technological advances and trial management tools that can be used to reduce the expenses incurred, explains Kim Boericke at i3.  
view
download pdf
Michael Rosenberg of Health Decisions, Inc discusses how the combined use of adaptive operations, adaptive designs and supporting technologies can enable the pharma industry to break the efficiency barrier and rise above its own limitations.  
view
download pdf
Susan Suchdev of IRW Consulting considers the questions that investigators ask themselves during clinical research about quality, risk assessment, patient recruitment and site selection, and summarises seven critical steps for clinical study success.  
view
download pdf
bullet
Regional trials
Emerging regions feature increasingly in the list of top countries where clinical trials are being performed. Looking at Turkey, Karen I Politis Virk at Language Connections assesses the linguistic and regulatory challenges one should consider before outsourcing clinical research to this market.  
view
download pdf
Jörg Taubel, Keith Berelowitzand Ulrike Lorch at Richmond Pharmacology Limited make a case for conducting early phase clinical research in the UK over other European countries, and identify opportunities available for pharma companies and CROs alike.  
view
download pdf
eCLINICAL, DATA MANAGEMENT & STATISTICAL ANALYSIS
Interactive voice response systems have evolved beyond the telephone to provide a variety of solutions, from web-based randomisation to sophisticated drug supply monitoring. Charles Gasman at PharmaNet Development Group discusses the role these systems will play in future clinical trials.  
view
download pdf
As the search for patients leads to an increased globalisation of trials, Hugh P Levaux and Jaime Lau at UBC consider how interactive voice or web response systems can optimise the clinical trial process and ease the integration of global economies, such as Asia, into the market.  
view
download pdf
Valdo Arnera of PHT Corporation makes a case for automating the collection of patient reported outcome data as a way to achieve regulatory compliance and ensure patient safety, while also enabling eClinical trials that are less expensive, more accurate and safer than paper-based research.  
view
download pdf
bullet
THERAPEUTICS
DEXA technology has had an enormous impact on the measurement of bone densitometry in the last 50 years, and will continue to provide an essential resource for organisations conducting clinical trials, as shown by Annelee Spano Lander at CoreLab Partners and independent consultant Reta C Rupich.
 
view
download pdf
Paola Antonini and Michael F Murphy at Worldwide Clinical Trials examine trials in emergency departments, and assess the challenges that researchers face when conducting studies in this unpredictable workplace.
 
view
download pdf
bullet
Supply Chain & Manufacturing
Biological products are tricky to transport, but with the right packaging and logistics methods in place, problems can be overcome and savings achieved, as Rachel Griffiths at Biotec Services International explains.
 
view
download pdf
Peter Soelkner at Vetter Pharma International asks if it is sensible to partner in the early clinical development period, and if so, what the drug developer should look for in a potential contract manufacturer.
 
view
download pdf
bullet
Central Labs
Patrice Hugo at Clearstone Central Laboratories makes the case for centralised laboratories over decentralised,pointing to their flexibility and ability to combine all parties’needs, as well as identifying key trends that will affect these labs in the near future.
 
view
download pdf
Green initiatives in the laboratory are important not only to minimise any impact on the environment, but they also have implications in terms of safety and cost reduction, as highlighted by Tim Hynes at DaVita Clinical Research.
 
view
download pdf
   
spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August, and November

News and Press Releases

PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

Philadelphia, USA – September 10, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce the acquisition of San Diego-based Sherpa Clinical Packaging (Sherpa), which expands PCI’s U.S. operations to the West Coast. The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s capabilities also enables PCI to better support customers from early phases of clinical development through to commercial launch.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement